Normothermia in Patients With Acute Cerebral Damage
Primary Purpose
Traumatic Brain Injury, Subarachnoid Hemorrhage
Status
Unknown status
Phase
Phase 4
Locations
Italy
Study Type
Interventional
Intervention
Diclofenac
Sponsored by
About this trial
This is an interventional treatment trial for Traumatic Brain Injury focused on measuring Fever, Acute cerebral damage, Normothermia, Diclofenac, ICU, Outcome, Intracranial pressure, Cerebral perfusion pressure, Traumatic brain injury, Subarachnoid hemorrhage
Eligibility Criteria
Inclusion Criteria:
- Patients with severe traumatic injury or subarachnoid hemorrhage in coma (GCS<8), intubated, mechanically ventilated with intracranial pressure (ICP) and invasive arterial pressure monitoring
Exclusion Criteria:
- Know adverse reactions with NSAI
- Platelets count < 20,000/dl
- Gastric or duodenal ulceration in active phase
- Hepatic insufficiency, cirrhosis or previous liver transplant
- Acute or chronic renal insufficiency
- Coronary insufficiency, acute myocardial infarct in the previous 6 month
- Barbiturate coma
- Patients in therapy with acetylsalicylic acid, lithium, digoxin, methotrexate and cyclosporin.
- Known or suspected pregnancy
Sites / Locations
- Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina ElenaRecruiting
Outcomes
Primary Outcome Measures
Maintenance of normothermia
Secondary Outcome Measures
Behaviour of intracranial pressure and cerebral perfusion pressure. Influence on six month outcome.
Full Information
NCT ID
NCT00491192
First Posted
June 25, 2007
Last Updated
September 19, 2007
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
1. Study Identification
Unique Protocol Identification Number
NCT00491192
Brief Title
Normothermia in Patients With Acute Cerebral Damage
Official Title
Normothermia in Patients With Acute Cerebral Damage
Study Type
Interventional
2. Study Status
Record Verification Date
June 2007
Overall Recruitment Status
Unknown status
Study Start Date
June 2007 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2009 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of our study is to verify wherever normothermia (achieved with diclofenac administration) may improve intracranial pressure control and may limit secondary cerebral damage thus positively influencing outcome in patients with acute cerebral damage admitted to ICU.
Detailed Description
Pyrexia can exacerbate ischemic neuronal damage and physiological dysfunction after traumatic brain injury and subarachnoid hemorrhage.Fever also represent an important issue occurring in 78% of patients with acute cerebral damage admitted to intensive care unit (ICU). For those patients, normothermia is actually recommended in order to reduce secondary cerebral damage and to control intracranial pressure, that are known to worsen long term prognosis. Our primary endpoint is to maintain normothermia in patients with acute cerebral damage (axillary temperature < 38°C or internal temperature < 38,8°C) administering diclofenac. We will also investigate the corresponding behaviour of intracranial pressure and cerebral perfusion pressure.
Comparison(s): We will compare two different doses of subcutaneous diclofenac (0,35 mg/kg - 1/3 a vial - vs 0,5 mg/Kg - 1/2 vial) to continuous intravenous of 0,48 mg/kg diclofenac for 12 hours.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Traumatic Brain Injury, Subarachnoid Hemorrhage
Keywords
Fever, Acute cerebral damage, Normothermia, Diclofenac, ICU, Outcome, Intracranial pressure, Cerebral perfusion pressure, Traumatic brain injury, Subarachnoid hemorrhage
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Diclofenac
Primary Outcome Measure Information:
Title
Maintenance of normothermia
Time Frame
within 14 days from ICU admission
Secondary Outcome Measure Information:
Title
Behaviour of intracranial pressure and cerebral perfusion pressure. Influence on six month outcome.
Time Frame
Within 14 days from ICU admission/Six months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with severe traumatic injury or subarachnoid hemorrhage in coma (GCS<8), intubated, mechanically ventilated with intracranial pressure (ICP) and invasive arterial pressure monitoring
Exclusion Criteria:
Know adverse reactions with NSAI
Platelets count < 20,000/dl
Gastric or duodenal ulceration in active phase
Hepatic insufficiency, cirrhosis or previous liver transplant
Acute or chronic renal insufficiency
Coronary insufficiency, acute myocardial infarct in the previous 6 month
Barbiturate coma
Patients in therapy with acetylsalicylic acid, lithium, digoxin, methotrexate and cyclosporin.
Known or suspected pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nino Stocchetti, MD
Phone
0039.02.5503.5517
Email
stocchet@policlinico.mi.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nino Stocchetti, MD
Organizational Affiliation
Ospedale Maggiore Policlinico Mangiagalli e Regina Elena
Official's Role
Study Director
Facility Information:
Facility Name
Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena
City
Milan
ZIP/Postal Code
20122
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Ghisoni, MD
First Name & Middle Initial & Last Name & Degree
Katia Canavesi, MD
12. IPD Sharing Statement
Learn more about this trial
Normothermia in Patients With Acute Cerebral Damage
We'll reach out to this number within 24 hrs